Trade

with

Corcept Therapeutics Inc
(NASDAQ: CORT)
AdChoices
3.00
+0.08
+2.74%
After Hours :
3.00
0.00
0.00%

Open

2.89

Previous Close

2.92

Volume (Avg)

183.71k (211.14k)

Day's Range

2.88-3.08

52Wk Range

1.60-4.49

Market Cap.

303.37M

Dividend Rate ( Yield )

-

Beta

1.39

Shares Outstanding

101.12M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 10.36M

    • Net Income

    • -46.01M

    • Market Cap.

    • 303.37M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -255.89

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.39

    • Forward P/E

    • -

    • Price/Sales

    • 17.70

    • Price/Book Value

    • 87.72

    • Price/Cash flow

    • -8.81

      • EBITDA

      • -41.42M

      • Return on Capital %

      • -70.14

      • Return on Equity %

      • -198.58

      • Return on Assets %

      • -70.14

      • Book Value/Share

      • 0.03

      • Shares Outstanding

      • 101.12M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.22

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 209.40

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 118.28

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 97.12

            • 82.75

            • Pre-Tax Margin

            • -255.89

            • 39.38

            • Net Profit Margin

            • -255.89

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 8.01

              • 0.76

              • Current Ratio

              • 2.96

              • 2.92

              • Quick Ratio

              • 2.72

              • 2.35

              • Interest Coverage

              • -9.11

              • 38.02

              • Leverage Ratio

              • 12.86

              • 2.21

              • Book Value/Share

              • 0.03

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -7.35

                • 238.10

                • P/E Ratio 5-Year High

                • -11.69

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.93

                • 124.82

                • Price/Sales Ratio

                • 18.80

                • 8.94

                • Price/Book Value

                • 93.46

                • 8.12

                • Price/Cash Flow Ratio

                • -8.81

                • 47.85

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -198.58

                        (-105.70)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -70.14

                        (-81.40)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -69.56

                        (-91.20)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 0.55

                      • 1.48

                      • Asset Turnover

                      • 0.27

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -41.50M
                      Operating Margin
                      -400.66
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -8.81
                      Ownership

                      Institutional Ownership

                      53.44%

                      Top 10 Institutions

                      49.45%

                      Mutual Fund Ownership

                      19.19%

                      Float

                      53.43%

                      5% / Insider Ownership

                      7.98%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Federated Kaufmann Fund

                      •  

                        10,172,048

                      • 9.62

                      • 10.06

                      • AST Federated Aggressive Growth

                      •  

                        1,495,700

                      • 0.00

                      • 1.48

                      • Federated Kaufmann Small Cap Fund

                      •  

                        1,325,000

                      • 4.74

                      • 1.31

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,065,416

                      • 0.00

                      • 1.05

                      • iShares Russell 2000 (AU)

                      •  

                        847,998

                      • -1.00

                      • 0.91

                      • Vanguard Extended Market Index Fund

                      •  

                        762,322

                      • 0.31

                      • 0.75

                      • iShares Russell 2000 Growth

                      •  

                        381,985

                      • 0.77

                      • 0.41

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        220,514

                      • 0.00

                      • 0.22

                      • Federated Kaufmann

                      •  

                        219,700

                      • 10.96

                      • 0.22

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Longitude Venture Partners

                      •  

                        13,433,573

                      • 0.00%

                      • 13.46

                      • Federated Global Inv Mgmt Corp

                      •  

                        13,335,690

                      • +794.27%

                      • 13.19

                      • Ingalls & Snyder LLC

                      •  

                        6,655,073

                      • +2.39%

                      • 6.58

                      • Sutter Hill Ventures

                      •  

                        5,420,353

                      • 0.00%

                      • 5.43

                      • Investors Finance Co PLC

                      •  

                        3,454,745

                      • 0.00%

                      • 3.42

                      • BlackRock Fund Advisors

                      •  

                        2,330,742

                      • +0.27%

                      • 2.30

                      • Vanguard Group, Inc.

                      •  

                        2,148,244

                      • +0.89%

                      • 2.12

                      • Morgan Stanley Smith Barney LLC

                      •  

                        1,466,817

                      • +1.94%

                      • 1.45

                      • State Street Corp

                      •  

                        908,433

                      • +13.96%

                      • 0.90

                      • Northern Trust Investments, N.A.

                      •  

                        605,872

                      • -7.66%

                      • 0.60

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical Company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic an...mored psychiatric and oncologic disorders. Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; ...moreand developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.lessless

                      Key People

                      Joseph K. Belanoff,M.D.

                      CEO/Co-Founder/Director/President

                      James N. Wilson

                      Chairman of the Board/Director

                      Mr. G. Charles Robb

                      CFO/Secretary

                      Anne M. LeDoux

                      Chief Accounting Officer/Controller/Vice President

                      David L. Mahoney

                      Director

                      • Corcept Therapeutics Inc

                      • 149 Commonwealth Drive

                      • Menlo Park, CA 94025

                      • USA.Map

                      • Phone: +1 650 327-3270

                      • Fax: +1 650 327-3218

                      • corcept.com

                      Incorporated

                      1998

                      Employees

                      50

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: